Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(01): 1-3
DOI: 10.4103/0971-5851.68844
EDITORIAL

Oral systemic therapy: Not all "win-win"

G S Bhattacharyya
Department of Medical Oncology and Clinical Hematology, AMRI Hospitals, Gariahat Road, Orchid Nursing Home, C I T Road, Scheme VI M, Phoolbagan, Kolkata, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
19 November 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Toffoli G, Corona G, Basso B, Boiocchi M. Phar-macokinetic optimization of treatment with oral etoposide. Clin Pharmacokinet 2004;43:441-66.
  • 2 Davis M. Gender differences in p-glycoprotein: Drug toxicity and response. J Clin Oncol 2005;23:6439-40.
  • 3 Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be mini-mized? Crit Rev Oncol Hematol 2005;55:117-42.
  • 4 Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006;12:5496-502.
  • 5 Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-7.
  • 6 Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3 rd , Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
  • 7 Lembersky BC, Wieand HS, Petrelli NJ, O′Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carci-noma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64.
  • 8 Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.
  • 9 Borner M, Schsffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Peters G, Grynwald V, Wanders J, de Boer R, Mrtin C, Fumoleau P (2000) A randomized crossover trial comparing oral UFT Uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 19:741.
  • 10 Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the functional assessment of cancer therapy-colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8:181-95.